Dopamine transporter (DAT) autoantibodies are a potential marker of the psychopharmacological treatment response, as basal DAT antibodies are elevated in untreated patients with ADHD (Giana et al. 2015). This evidence concerns the gene SLC6A3 and attention deficit-hyperactivity disorder.